Endometrial cancer and tamoxifen.
Burke
Catherine
C
Laura Lee Blanton Gynecologic Oncology Center at the University of Texas MD Anderson Cancer Center in Houston, USA.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002273:Carcinogens / Q000009:adverse effects*; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000175:diagnosis*; D005260:Female; D006801:Humans; D015907:Hysteroscopy; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis*; D011960:Receptors, Estrogen / Q000032:analysis; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects*; D014463:Ultrasonography; D014592:Uterine Hemorrhage / Q000139:chemically induced*
D018931:Antineoplastic Agents, Hormonal; D002273:Carcinogens; D011960:Receptors, Estrogen; D013629:Tamoxifen